The bill mandates the Agency for Health Care Administration to conduct or contract for a detailed fiscal impact study to assess the feasibility of implementing provisions related to discounted drug prices under the 340B Drug Pricing Program. Key requirements of the study include evaluating the necessity for drug manufacturers to sell drugs to Medicaid pharmacies at the 340B discounted price, ensuring that pharmacy benefits managers pay the same discounted price plus a professional dispensing fee, and requiring drug wholesalers to adhere to similar pricing standards. Additionally, the bill stipulates that Medicaid pharmacies can only provide covered drugs at the discounted price to Medicaid recipients.

The results of the study are to be submitted to the Governor, the President of the Senate, and the Speaker of the House of Representatives by January 31, 2027. The act is set to take effect on July 1, 2026.